Patents for A61P 35 - Antineoplastic agents (221,099)
09/2007
09/05/2007CN100335132C Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
09/05/2007CN100335123C Method for improving oral drug living thing availability, composition and reagent box
09/05/2007CN100335121C Methods and compositions relating to HPV-associated pre-cancerous and cancerous growths, including CIN
09/05/2007CN100335092C Externally applied Chinese medicine for treating cancer pain
09/04/2007US7265260 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
09/04/2007US7265229 Method for synthesizing macrosphelides
09/04/2007US7265228 N-(alpha-methylolbenzyl)1-(aminoethyl)- or 1-(aminocarbonyl)-2-aryl(especially phenyl or benzodioxanyl)-2-hydroxyethylamine intermediates for enantiomeric synthesis of amino ceramide-like compounds
09/04/2007US7265227 Piperidine derivatives useful as modulators of chemokine receptor activity
09/04/2007US7265225 For therapy of cancer
09/04/2007US7265221 Pyrrolo[2,3-d]pyrimidine compounds
09/04/2007US7265157 Sustained release compositions, process for producing the same and use thereof
09/04/2007US7265154 Valproic acid and derivatives thereof as histone deacetylase inhibitors
09/04/2007US7265143 C-4 substituted retinoids
09/04/2007US7265139 RXR activating molecules
09/04/2007US7265137 Phenylacetic acid derivative; hypoglycemic agents; antilipemic agents; anticholesterol agents; cardiovascular disorders
09/04/2007US7265136 Substituted stilbene compounds with vascular damaging activity
09/04/2007US7265124 Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
09/04/2007US7265123 Heterocyclic compounds
09/04/2007US7265119 For therapy of nicotine dependency
09/04/2007US7265114 Antiproliferative agents for smooth muscle cells; antiinflammatory agents for endothelial cells; restenosis, atherosclerosis
09/04/2007US7265113 Anticancer agents; antiinflammatory agents, for therapy of rheumatoid arthritis
09/04/2007US7265108 For example, 6-[2-[4-(2-fluorophenoxymethyl)piperidino]ethyl]-1H-pyrazin-2-one; therapeutic or prophylactic agent for diabetic neuralgia, HIV neuralgia, postherpetic neuralgia, nerve system disorders
09/04/2007US7265105 Pyrrolobenzodiazepines
09/04/2007US7265100 Separation of regioisomers of metal phthalocyanines
09/04/2007US7264945 IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
09/04/2007US7264940 Detecting the expression of a G-protein coupled receptor, identifying agonists or antagonists of the receptor
09/04/2007US7264928 whereby a DNA sample is tested for the presence of polymorphic allele; solid phase synthesis
09/04/2007US7264820 Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline
09/04/2007US7264814 wherein at least one non-essential gene for replication thereof is inactivated; side effect reduction
09/04/2007US7264810 Scaffolds comprising epitopes and genetic engineered proteins of bacteriophages, used as vaccines, anticarcinogenic agents or antiallergens
09/04/2007US7264805 Proteins with a high immunoreactivity and a method for the production thereof
09/04/2007US7264798 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
09/04/2007CA2409999C Optical polymer mixtures for gastric retentive tablets
09/04/2007CA2336194C 1-(aminoalkyl)-3-quinoxaline-2-one derivatives for the preparation of compounds having an antioxidant action
08/2007
08/30/2007WO2007098504A1 Prodrugs of curcumin analogs
08/30/2007WO2007098474A1 Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
08/30/2007WO2007098033A2 Feedback prodrug
08/30/2007WO2007097937A1 Pyrrolidine derivatives as erk inhibitors
08/30/2007WO2007097812A2 Therapeutic anti-her2 antibody fusion polypeptides
08/30/2007WO2007097648A1 Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
08/30/2007WO2007097647A1 Methods of treating cancer
08/30/2007WO2007097473A1 Organic magnetic nanocomplex having functional molecule introduced therein
08/30/2007WO2007097470A2 Fused nitrogen- comprising heterocyclic compound
08/30/2007WO2007097455A1 Novel compound isolated from plant 'pau-ferro'
08/30/2007WO2007097418A1 Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent
08/30/2007WO2007097412A1 Oil-in-water emulsion composition containing licorice-derived polyphenol
08/30/2007WO2007097370A1 IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND
08/30/2007WO2007097358A1 Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
08/30/2007WO2007097010A1 Substance fki-2342 and process for production thereof
08/30/2007WO2007096471A1 Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors
08/30/2007WO2007096395A1 Indolopyridines as eg5 kinesin modulators
08/30/2007WO2007096393A1 Indolopyridines as eg5 kinesin modulators
08/30/2007WO2007096351A1 2,4-diaminopyrimidine derivatives for the treatment and/or prevention of cancer, infections, inflammatory and autoimmune disorders
08/30/2007WO2007096334A1 Pyrrolopyrrolones active as kinase inhibitors
08/30/2007WO2007096315A1 4-phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as plk1 inhibitors
08/30/2007WO2007096278A1 Dendritic cells transiently transfected with a membrane homing polypeptide and their use
08/30/2007WO2007096174A1 Rapamycin derivatives for treating neuroblastoma
08/30/2007WO2007095850A1 A pharmaceutical composition of docetaxel, preparation and use
08/30/2007WO2007095828A1 Dihydroporphine e6 zinc complexes as photosensitizer, their preparation and their use
08/30/2007WO2007095812A1 Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
08/30/2007WO2007095749A1 Cytotoxicity mediation of cells evidencing surface expression of trop-2
08/30/2007WO2007095748A1 Cancerous disease modifying antibody 141205-05
08/30/2007WO2007095747A1 Cytotoxicity mediation of cells evidencing surface expression of cd59
08/30/2007WO2007095746A1 Cancerous disease modifying antibodies
08/30/2007WO2007095729A1 Cytotoxicity mediation of cells evidencing surface expression of cd63
08/30/2007WO2007095722A1 Doxorubicin formulations for anti-cancer use
08/30/2007WO2007079214A3 Prokineticin 2 receptor antagonists
08/30/2007WO2007079169A3 Treatment for acute myeloid leukemia
08/30/2007WO2007079163A3 Prokineticin 1 receptor antagonists
08/30/2007WO2007079146A8 Treatment for non-hodgkin's lymphoma
08/30/2007WO2007077203A3 Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
08/30/2007WO2007073303A3 Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
08/30/2007WO2007071455B1 Sulfoximine-substituted pyrimidines , their preparation and use as drugs
08/30/2007WO2007057399A3 Treatment of cancer with indole derivatives
08/30/2007WO2007054279A3 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
08/30/2007WO2007042912A3 Heterocyclic compounds as pstat3/il-6 inhibitors
08/30/2007WO2007036802A3 Sublingual dosage form comrising vitamin d analogue, in particular calcitriol
08/30/2007WO2007014278A3 B-cell reduction using cd37-specific and cd20-specific binding molecules
08/30/2007WO2007010394A3 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
08/30/2007WO2007000676A3 Guanosine-rich oligonucleotides as agents for inducing cell death in eukaryotic cells
08/30/2007WO2006134497A3 Uses of recombinant super-compound interferons
08/30/2007WO2006119211A3 Methods and compositions for treating ocular disorders
08/30/2007WO2000001393A8 OLIGONUCLEOTIDE INHIBITORS OF bcl-xL
08/30/2007US20070203339 Process for Preparation of Cyclic Prodrugs of PMEA and PMPA
08/30/2007US20070203337 Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase
08/30/2007US20070203223 Via amino ceramide-like compounds; lowering glycosphingolipid concentrations; Fabry's disease, Gaucher's disease
08/30/2007US20070203217 Substituted stilbenes and their reactions
08/30/2007US20070203193 Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
08/30/2007US20070203189 having proinflammatory cytokine production inhibiting properties, in particular tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-12 (IL-12) inhibiting properties, used for the prevention or the treatment of inflammatory and/or autoimmune diseases
08/30/2007US20070203185 Therapeutical Composition Containing Dentritic Cells And Use Thereof
08/30/2007US20070203184 Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them
08/30/2007US20070203166 Administering non-gas containing nanoparticles comprising a mixture of select lipids capable of being internalized within a targeted tissue or cell sufficient to achieve a desired effect and anticancer agent
08/30/2007US20070203138 Novel Compounds and Compositions as Cathepsin S Inhibitors
08/30/2007US20070203088 Detection and modulation of IAPs and NAIP for the diagnosis and treatment of proliferative disease
08/30/2007US20070203057 Compounds and methods for modulating adhesion molecule function
08/30/2007US20070202574 Novel Saccharothrix Strain an Antibiotics Derived Therefrom, i.e. Mutactimycins and Aldgamycins
08/30/2007US20070202516 Gene detection assay for improving the likelihood of an effective response to an egfr antagonist cancer therapy
08/30/2007US20070202501 Proteins Expressed In Ink Cells
08/30/2007US20070202198 Process of obtaining thylakoids from photosynthetic organisms; plant fractions obtained from the process; pure thylakoids; and methods of use of thylakoids as ROS scavengers, photo-protectors, biosensors biofilters and bioreactors
08/30/2007US20070202160 Solid-state form of celecoxib having enhanced bioavailability